FCF Pharmaceutical Market Study – 2020 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Pharmaceutical Market Study – 2020”.

Based on available data from European pharmaceutical providers, the FCF Pharmaceutical Market Study is a detailed and comprehensive analysis of the pharmaceutical sector and especially addresses the European small- / midcap market segment.

Key findings of the FCF Pharmaceutical Market Study (September 2020):

  • Revenue is expected to increase by +0.3% from ’19 to ’20
  • EBITDA is expected to increase by +2.6% from ’19 to ’20
  • EBIT is expected to decrease by -10.8% from ’19 to ’20
  • EV / EBITDA valuation multiple slightly decreased from 12.2x in ’19 to 12.0x LTM
  • Net leverage decreased from 2.1x in ’19 to 1.9x LTM
  • Interest cover ratio increased from 57.5x in ’19 to 67.2x LTM
  • The number of Private Equity (PE) deals increased from 30 in ’18 to 37 in ’19 and M&A deal activity decreased from 40 in ’18 to 33 in ‘19

To access the full report, please click here.

By Marcel Lange, Tristan Blümli, Marco Buonafede and Yasmin Herrmann

Share on linkedin
Scroll Up